rs147647315 — SLC22A12 URAT1 R90H

SLC22A12 R90H — A Rare URAT1 Variant That Silences Urate Retention

Your kidneys perform a quiet daily miracle: filtering 7–8 grams of uric acid from your blood, then reabsorbing roughly 90% of it back before it can reach the urine. The protein that does most of this recapture is URAT1 (Urate Transporter 1)¹¹ URAT1 (Urate Transporter 1)
Encoded by SLC22A12. An antiporter on the apical membrane of proximal tubule cells that exchanges urate for organic anions (lactate, nicotinate, pyrazinoate), rescuing filtered uric acid back into the bloodstream. Without URAT1, most uric acid would simply spill into the urine. The R90H variant (rs147647315) introduces a histidine at position 90 of the URAT1 protein in place of the usual arginine, destabilising the transporter and impairing its urate-reabsorption function. The result is persistently low serum uric acid — a condition called renal hypouricemia²² renal hypouricemia
A phenotype defined by serum uric acid below 2 mg/dL caused by impaired renal reabsorption; most carriers are asymptomatic but can develop exercise-induced acute kidney injury during vigorous or prolonged physical activity type 1 (RHUC1).

Unlike the more studied W258X variant (rs121907892) that predominates in East Asian populations, R90H (rs147647315) is the primary SLC22A12 loss-of-function allele in populations of African ancestry. A genome-wide association study³³ genome-wide association study
Chen G et al. Refining genome-wide associated loci for serum uric acid in individuals with African ancestry. Hum Mol Genet, 2020 in more than 9,000 continental Africans and African Americans identified rs147647315 as the strongest signal at the SLC22A12 locus (P = 6.65 × 10⁻²⁵) and the sole causal variant at that locus when functional annotation was applied to kidney tissue.

The Mechanism

The arginine at position 90 normally forms a stable hydrogen bond with glutamine 93, helping to anchor that region of the protein. When histidine replaces arginine, the bond lengthens from 2.3 Å (wild-type) to 3.1 Å — at the edge of the hydrogen-bond distance range. This weakened interaction destabilises the local protein domain and likely impairs the folding or membrane integration of URAT1. Structural modelling⁴⁴ Structural modelling
Zhou Z et al. Renal hypouricemia caused by novel compound heterozygous mutations in the SLC22A12 gene: a case report with literature review. BMC Med Genet, 2018 of compound heterozygous patients carrying R90H alongside another truncating mutation confirmed that the resulting protein is functionally impaired, producing the hallmark biochemical phenotype: dramatically elevated fractional excretion of uric acid and very low serum urate.

The broader class of nonfunctional URAT1 variants — of which R90H is one — produces protein that is not properly membrane-localised. Without stable insertion into the apical tubule membrane, URAT1 cannot exchange urate and the kidney's urate recapture capacity is sharply reduced.

The Evidence

African ancestry GWAS: Chen et al. (2020)⁵⁵ Chen et al. (2020)
Chen G et al. Refining genome-wide associated loci for serum uric acid in individuals with African ancestry. Hum Mol Genet, 2020 is the pivotal study for rs147647315 specifically. Among 9,133 participants of African descent, rs147647315 was identified as both the strongest statistical association at the SLC22A12 locus (P = 6.65 × 10⁻²⁵) and the sole functionally prioritised causal variant at that locus, with kidney tissue identified as the relevant biological context. This work established that the A allele of rs147647315 independently drives the serum uric acid-lowering signal at SLC22A12 in this ancestry group.

Phenotypic characterisation of nonfunctional URAT1: Sakiyama et al. (2016)⁶⁶ Sakiyama et al. (2016)
Sakiyama M et al. The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep, 2016 studied 1,993 gout patients and 2,499 health examinees in Japan. Nonfunctional URAT1 variants (R90H and W258X combined) were absent in every single gout case. Among health examinees, males carrying one nonfunctional allele had serum uric acid 2.19 mg/dL lower than those without; females showed 1.08 mg/dL lower levels. Two nonfunctional alleles reduced urate by 5.42 mg/dL (males) and 3.89 mg/dL (females) — a sex-dependent dosage effect (interaction P = 1.5 × 10⁻¹²).

Toyoda et al. (2021)⁷⁷ Toyoda et al. (2021)
Toyoda Y et al. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. Rheumatology (Oxford), 2021 quantified the anti-gout protection at a reciprocal OR of 29.6 (P = 7.66 × 10⁻⁸) across all dysfunctional URAT1 variants combined, confirming that functional loss of URAT1 — regardless of the specific mutation — provides among the strongest single-variant gout protection documented in humans.

Large-scale Japanese epidemiology: Kawamura et al. (2021)⁸⁸ Kawamura et al. (2021)
Kawamura Y et al. A proposal for practical diagnosis of renal hypouricemia. Biomedicines, 2021 studied 30,685 Japanese health examinees and confirmed that nonfunctional URAT1 variants (including R90H) significantly increased fractional excretion of uric acid (P = 1.27 × 10⁻⁴⁶ in males) and decreased serum uric acid (P = 2.47 × 10⁻⁵³ in males). The study proposed that FEUA and SUA biomarkers together can guide clinical suspicion of URAT1 variant burden before genetic testing.

Exercise-induced AKI risk: Among individuals with complete or near-complete URAT1 loss of function (homozygous or compound heterozygous for nonfunctional variants), vigorous physical activity can trigger exercise-induced acute kidney injury (EIAKI)⁹⁹ acute kidney injury (EIAKI)
AKI presenting hours after intense exercise with flank pain, haematuria, and oliguria; believed to result from uric acid surges in the tubular lumen exceeding solubility when renal excretion is maximal and urine is concentrated. Kawamura et al. (2021)¹⁰¹⁰ Kawamura et al. (2021) and multiple case series confirm that homozygous or compound heterozygous URAT1 loss-of-function — including R90H paired with W258X or another nonfunctional allele — accounts for most clinically documented EIAKI.

Practical Actions

For heterozygous carriers (AG), the picture is straightforward: moderately lower serum uric acid and strong protection against gout. No specific intervention is required beyond awareness. Exercise is safe with normal hydration precautions.

For the extremely rare homozygous carrier (AA), or compound heterozygous carriers (one A allele at this locus plus a nonfunctional allele at another URAT1 position), the full loss-of-function phenotype produces clinically significant hypouricemia with EIAKI risk. These individuals should be followed by a nephrologist and should understand the pre-exercise hydration and urinary alkalinisation protocols that reduce tubular urate crystal formation risk.

Interactions

rs121907892 (SLC22A12 W258X): The W258X truncating variant is the most common nonfunctional URAT1 allele in East Asian populations. Compound heterozygosity for R90H and W258X — one copy of each nonfunctional allele — produces the same near-total URAT1 loss-of-function as homozygosity for either variant alone. EIAKI risk is highest in this compound heterozygous state. Reports from Japanese patients include R90H/W258X compound heterozygotes with frank hypouricemia.

rs121907896 (SLC22A12 R90H — Japanese-population allele): A separate rsid (rs121907896) refers to what appears to be the same or an overlapping R90H variant designation found predominantly in East Asian populations in the literature. Population genetics of the SLC22A12 locus differs substantially by ancestry — rs147647315 is the African-enriched GWAS signal, while rs121907896 is the Japan-characterised pathogenic R90H allele. Full haplotype resolution in multi-ancestry datasets has not been published.

rs475688 and rs3825016 (SLC22A12 regulatory and coding variants): These common SLC22A12 variants act in the opposite direction — they increase URAT1 activity and raise serum uric acid. Carriers of the rs147647315 A allele alongside risk alleles at rs475688 or rs3825016 would have competing influences on the URAT1 system; the rare protective allele is expected to dominate at the transporter level, but systemic urate outcomes would depend on other pathway variants (SLC2A9, ABCG2).